Page last updated: 2024-10-29

ifosfamide and Neoplasms, Otorhinolaryngologic

ifosfamide has been researched along with Neoplasms, Otorhinolaryngologic in 1 studies

Research Excerpts

ExcerptRelevanceReference
"In three new approved indications (non Hodgkin's lymphoma, Hodgkin's lymphoma and acute lymphoblastic leukaemia) and in three previously existing indications (ovarian cancer, soft tissue sarcomas and osteogenic sarcomas), non comparative trials show that ifosfamide can induce tumour regression in patients who relapse after a first course of chemotherapy (sometimes containing cyclophosphamide)."3.70Ifosfamide: new idications-new dose strength. Limited evidence of effectiveness. ( , 1998)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Other Studies

1 other study available for ifosfamide and Neoplasms, Otorhinolaryngologic

ArticleYear
Ifosfamide: new idications-new dose strength. Limited evidence of effectiveness.
    Prescrire international, 1998, Volume: 7, Issue:34

    Topics: Adult; Antineoplastic Agents, Alkylating; Breast Neoplasms; Child; Clinical Trials as Topic; Cycloph

1998